Diagnosis and management of drug-associated interstitial lung disease

被引:75
作者
Müller, NL
White, DA
Jiang, H
Gemma, A
机构
[1] Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] AstraZeneca KK, Osaka, Japan
[5] Nippon Med Coll, Tokyo 113, Japan
关键词
interstitial lung disease; drug-associated ILD; lung cancer; NSCLC; algorithm;
D O I
10.1038/sj.bjc.6602064
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Symptoms of drug-associated interstitial lung disease (ILD) are nonspecific and can be difficult to distinguish from a number of illnesses that commonly occur in patients with non-small-cell lung cancer (NSCLC) on therapy. Identification of drug involvement and differentiation from other illnesses is problematic, although radiological manifestations and clinical tests enable many of the alternative causes of symptoms in advanced NSCLC to be excluded. In lung cancer patients, high-resolution computed tomography (HRCT) is more sensitive than a chest radiograph in evaluating the severity and progression of parenchymal lung disease. Indeed, the use of HRCT imaging has led to the recognition of many distinct patterns of lung involvement and, along with clinical signs and symptoms, helps to predict both outcome and response to treatment. This manuscript outlines the radiology of drug-associated ILD and its differential diagnosis in NSCLC. An algorithm that uses clinical tests to exclude alternative diagnoses is also described.
引用
收藏
页码:S24 / S30
页数:7
相关论文
共 36 条
[1]   Radiation-induced and chemotherapy-induced pulmonary injury [J].
Abid, SH ;
Malhotra, V ;
Perry, MC .
CURRENT OPINION IN ONCOLOGY, 2001, 13 (04) :242-248
[2]  
[Anonymous], 2002, AM J RESP CRIT CARE, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]
[3]  
Aviram G, 2001, CAN ASSOC RADIOL J, V52, P385
[4]   Gemcitabine-induced severe pulmonary toxicity [J].
Barlési, F ;
Villani, P ;
Doddoli, C ;
Gimenez, C ;
Kleisbauer, JP .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (01) :85-91
[5]  
Baughman RP, 1994, CLIN PULM MED, V1, P223
[6]   Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions [J].
Bookman, MA ;
Kloth, DD ;
Kover, PE ;
Smolinski, S ;
Ozols, RF .
ANNALS OF ONCOLOGY, 1997, 8 (06) :611-614
[7]  
BUZDAR AU, 1980, CANCER, V45, P236, DOI 10.1002/1097-0142(19800115)45:2<236::AID-CNCR2820450207>3.0.CO
[8]  
2-0
[9]  
CHANG AYC, 1986, CANCER, V57, P2285, DOI 10.1002/1097-0142(19860615)57:12<2285::AID-CNCR2820571209>3.0.CO
[10]  
2-4